Bilastine Dosing Recommendations
For adults and adolescents ≥12 years, bilastine 20 mg once daily is the standard dose; for children aged 6-11 years, 10 mg once daily is recommended; and for children aged 2-5 years (where approved), 10 mg once daily is also appropriate. 1
Age-Specific Dosing
Adults and Adolescents (≥12 years)
- Standard dose: 20 mg once daily 2
- This dose has been extensively validated for allergic rhinoconjunctivitis and urticaria
- No dosage adjustments needed for renal or hepatic impairment, or in elderly patients 2
Children 6-11 Years
- 10 mg once daily 1, 3
- Pharmacokinetic studies confirm that this pediatric dose achieves similar plasma exposure to the adult 20 mg dose (median pediatric/adult ratios for AUC and Cmax were 0.93 and 0.91, respectively) 3
- Safety profile comparable to placebo in this age group 3
Children 2-5 Years
- 10 mg once daily 1, 4
- Approved in select regions (Mexico, some African countries) for children ≥2 years 5
- Pharmacokinetic modeling demonstrates that body weight and age do not significantly affect drug clearance or distribution in this age range, supporting the 10 mg dose across the 2-11 year age spectrum 4
- Peak plasma concentrations occur approximately 1 hour after administration 4
Children 4-11 Years (Specific Weight Criteria)
- For children weighing ≥16 kg aged 4-11 years: 10 mg once daily 1
- This weight-based criterion is particularly relevant in certain regulatory jurisdictions (Canada approves ≥4 years; Europe approves ≥6 years) 5
Formulation Considerations
Bilastine is available as:
Important Clinical Caveats
Timing with food: Bilastine absorption is affected by food intake. While not explicitly detailed in the provided guidelines, standard practice recommends administration 1 hour before or 2 hours after meals for optimal absorption.
Up-dosing in refractory urticaria: The 2025 CSU guidelines recommend considering up-dosed second-generation antihistamines (2-4 times the approved dose) if standard dosing fails to control symptoms 1. For bilastine, this would translate to 40-80 mg daily in adults, though this is off-label use.
Drug interactions: Bilastine undergoes negligible metabolism and does not interact with the CYP450 system, minimizing drug-drug interaction potential 2. It is a P-glycoprotein substrate, which actually limits CNS penetration and reduces sedation risk 6.
Safety profile: Bilastine demonstrates no anticholinergic effects, no cardiotoxicity, minimal CNS penetration, and does not enhance alcohol effects 2, 6. Treatment-emergent adverse events in children are comparable to placebo 3, 4.